# ILUSTRO (NCT03505320)

> A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03505320
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Pharmacokinetics of Zolbetuximab; Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer; Pharmacokinetics of Oxaliplatin; Pharmacokinetics of Fluorouracil Bolus (5-FU)
- Interventions: zolbetuximab; oxaliplatin; leucovorin; fluorouracil; Pembrolizumab; folinic acid; nivolumab; Docetaxel
- Enrollment: 143
- Primary outcome: Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1)

## Commentary we found

- X threads: 28
- YouTube: 17
- Podcasts: 16

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ilustro-nct03505320

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03505320", "email": "<work email>"}; the inbox owner confirms by the emailed link.